Precision Nanomedicine

PRNANO is an open access, international society journal, published online only. Articles appear continuously on a rolling basis, then organized into quarterly issues (January, April, July, and October). All content is licensed under the Creative Commons CC BY-NC-SA 4.0 license. The mission of our journal is to promote all practical, rational, and progressive aspects of nanomedicine including theory and practice. Authors are invited to send submissions in basic science, translational, preclinical, and clinical research. PRNANO accepts original manuscripts, as well as replication studies and discussions of negative results as long as they are clearly marked as such and move the field forward. Aim and scope of the journal is to provide a good quality and supportive publishing forum with quick turnaround time for nanomedicine researchers and provide reliable and cutting-edge information to their societies and to libraries without additional cost.

NOTE: We are signatories of the San Francisco Declaration on Research Assessment and we advise against the use of journal-based metrics, such as Journal Impact Factors, as a surrogate measure of the quality of individual research articles, to assess an individual scientist’s contributions, or in hiring, promotion, or funding decisions. We support article-based metrics. There are no APC-s in 2019. In the future, our journal fees (if any) will always reflect realistic costs and will be clearly displayed on our home page. We follow the publication policies of WHO as well as the principles and guidelines of COPE.

Location: Andover, Massachusetts, United States
Members: 2
Latest Activity: May 1

Improving Innovation in Nano- Healthcare Funding

European countries have invested heavily in Nanomedicine over the last decade, however, the output has been much reduced by a lack of knowledge of how to innovate in a heavily regulated setting. This development failing is not unique to nanomedicine but is there to differing extents across most open innovation healthcare projects. The transition from research to development requires informed debate and high-quality data and is a very challenging milestone. Researchers often say they are developing a new drug, when they are in fact doing research – funders also use the terms (R or D) interchangeably - an unfortunate consequence of their academic training. A simple test is if you don’t know actually what you are developing - you are in research.

Discussion Forum

This group does not have any discussions yet.

Comment Wall


You need to be a member of Precision Nanomedicine to add comments!


Welcome - about us

Welcome! Nanopaprika was cooked up by Hungarian chemistry PhD student in 2007. The main idea was to create something more personal than the other nano networks already on the Internet. Community is open to everyone from post-doctorial researchers and professors to students everywhere.

There is only one important assumption: you have to be interested in nano!

Nanopaprika is always looking for new partners, if you have any idea, contact me at

Dr. András Paszternák, founder of Nanopaprika

Partner network:

Next partner events of TINC

We are Media Partner of:



© 2019   Created by András Paszternák, PhD (founder).   Powered by

Badges  |  Report an Issue  |  Terms of Service